Identificador persistente para citar o vincular este elemento:
http://hdl.handle.net/10662/20206
Títulos: | Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs |
Autores/as: | Campo Mozo, Paloma Ayuso Parejo, Pedro Salas, María Plaza, María del Carmen Cornejo García, José Antonio Doña, Inmaculada Torres, María José Blanca López, Natalia Canto, Gabriela Guéant, Jean Louis Sanak, Marek Blanca, Miguel |
Palabras clave: | Mediadores inflamatorios;Inflammatory mediators;Aspirin-exacerbated cutaneous disease;Enfermedad cutánea exacerbada por la aspirina;Lysine nasal challenge;Provocación nasal con lisina;Multiple nonsteroidal anti-inflammatory drug-induced urticaria/angioedema;Urticaria/angioedema inducido por múltiples antiinflamatorios no esteroideos;Nonsteroidal anti-inflammatory drugs;Antiinflamatorios no esteroideos |
Fecha de publicación: | 2013 |
Editor/a: | John Wiley & Sons Ltd |
Resumen: | Background: Multiple NSAID-induced urticaria/angioedema (MNSAID-UA) is an entity well differentiated from aspirin-exacerbated respiratory disease (AERD), although no detailed phenotype analysis has yet been performed. The objective was to evaluate the functional characteristics of MNSAID-UA subjects by ana- lyzing the response to nasal lysine–aspirin challenge and measurement of nasal inflammatory mediator release compared with AERD subjects and controls. Methods: The study included 85 subjects with confirmed hypersensitivity to NSAIDs (!3 episodes with >2 different NSAIDs or positive drug provocation) with either cutaneous (MNSAID-UA, n = 25) or respiratory manifestations (AERD, n = 60) and 30 tolerant controls (15 aspirin-tolerant asthmatic patients and 15 healthy controls). Nasal lavages at 0, 15, 60, and 120 min after lysine– aspirin challenge were analyzed for ECP, tryptase, PGE2, PGD2, LTD4, and LTE4. Results: Lysine nasal challenge was positive in 80% of the AERD cases but posi- tive only in 12% of the MNSAID-UA group. MNSAID-UA subjects showed no changes in nasal ECP, whereas subjects with AERD had increased levels of ECP, with the highest peak at 15 min after challenge (P < 0.05). Tryptase levels were higher in AERD compared with MNSAID-UA and controls with the highest release of tryptase at 60 min (P < 0.05). Significant increases in PGD2, LTD4, and LTE4 were observed in AERD (at 60 min for PGD2, LTD4, and LTE4) but not in MNSAID-UA or control subjects (P < 0.05). Conclusions: Data support the observation that MNSAID-UA, although sharing a common response with AERD to COX inhibitors, seems to have a distinctive phenotype, based on the response to nasal challenge and the release of inflamma- tory mediators. |
URI: | http://hdl.handle.net/10662/20206 |
ISSN: | 0105-4538 1398-9995 |
DOI: | 10.1111/all.12187 |
Colección: | DTMQU - Artículos |
Archivos
Archivo | Descripción | Tamaño | Formato | |
---|---|---|---|---|
all_12187.pdf ???org.dspace.app.webui.jsptag.ItemTag.accessRestricted??? | 313,78 kB | Adobe PDF | Descargar Pide una copia |
Este elemento está sujeto a una licencia Licencia Creative Commons